Literature DB >> 11739710

Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants.

Dominique Markine-Goriaynoff1, Jean-Paul Coutelier.   

Abstract

Immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch variants were derived from an IgG3 monoclonal antibody directed against the VP3 envelope glycoprotein of lactate dehydrogenase-elevating virus (LDV). Among the four antibodies, IgG2a delayed the onset and progression of LDV-induced polioencephalomyelitis more than did the other subclasses. This suggests that the IgG2a predominance observed in many IgG antibody responses elicited by live viruses could, at least under some circumstances, correspond to the selection of the best protection for the infected host.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11739710      PMCID： PMC135718          DOI： 10.1128/jvi.76.1.432-435.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  30 in total

1.  IFN-gamma-independent IgG2a production in mice infected with viruses and parasites.

Authors:  D Markine-Goriaynoff; J T van der Logt; C Truyens; T D Nguyen; F W Heessen; G Bigaignon; Y Carlier; J P Coutelier
Journal:  Int Immunol       Date:  2000-02       Impact factor: 4.823

2.  Neuropathogenicity and sensitivity to antibody neutralization of lactate dehydrogenase-elevating virus are determined by polylactosaminoglycan chains on the primary envelope glycoprotein.

Authors:  Z Chen; K Li; P G Plagemann
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

3.  The role of antibody concentration and avidity in antiviral protection.

Authors:  M F Bachmann; U Kalinke; A Althage; G Freer; C Burkhart; H Roost; M Aguet; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies.

Authors:  S T Ishizaka; P Piacente; J Silva; E M Mishkin
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

5.  A simple technique for the rapid enrichment of class and subclass hybridoma switch variants. A 1000-fold enrichment in half the time, for half the cost.

Authors:  G B Faguet; J F Agee
Journal:  J Immunol Methods       Date:  1993-10-15       Impact factor: 2.303

6.  Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons.

Authors:  S Ubol; B Levine; S H Lee; N S Greenspan; D E Griffin
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

7.  Coexistence in lactate dehydrogenase-elevating virus pools of variants that differ in neuropathogenicity and ability to establish a persistent infection.

Authors:  Z Chen; R R Rowland; G W Anderson; G A Palmer; P G Plagemann
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice.

Authors:  G Palladino; K Mozdzanowska; G Washko; W Gerhard
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.

Authors:  J J Schlesinger; M Foltzer; S Chapman
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

10.  Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein.

Authors:  J J Smucny; E P Kelly; P O Macarthy; A D King
Journal:  Am J Trop Med Hyg       Date:  1995-10       Impact factor: 2.345
View more
  39 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

2.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

Authors:  Sheng Zhang; Rafael Cubas; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Immunol       Date:  2009-04-18       Impact factor: 4.407

4.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

5.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

6.  Signals that drive T-bet expression in B cells.

Authors:  Arpita Myles; Patricia J Gearhart; Michael P Cancro
Journal:  Cell Immunol       Date:  2017-09-11       Impact factor: 4.868

7.  In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner.

Authors:  Heike Albert; Mattias Collin; Diana Dudziak; Jeffrey V Ravetch; Falk Nimmerjahn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

8.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

9.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

10.  Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Authors:  Madelyn R Schmidt; Lori W McGinnes-Cullen; Sarah A Kenward; Kristin N Willems; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.